Member Contact: Dr Mark Devlin
Industry: Biotech & Pharmaceuticals
Aculeus Therapeutics is a Biotech company based in Melbourne Australia, developing small molecule drugs that modulate the immune system for the treatment of cancer and other serious diseases. Aculeus is doing this by developing drugs that target the Stimulator of Interferon Genes (STING) biochemical pathway.
Aculeus in-licensed its lead programs, STING and ENPP1, in 2020 from the CRC for Cancer Therapeutics, a Public Private Partnership between a number of Australia’s leading Medical Research Institutes, Universities and Industry partners with a track record of scientific and commercial success.